INTERLEUKIN-2 AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS CONSOLIDATIVE IMMUNOTHERAPY AGAINST MINIMAL RESIDUAL DISEASE

被引：0
|
作者：
BOSLY, A
BRICE, P
HUMBLET, Y
DOYEN, C
FAILLE, A
CHATELAIN, B
FRANKS, C
GISSELBRECHT, C
SYMANN, M
机构：
[1] UNIV CATHOLIQUE LOUVAIN, ONCOL & HEMATOL EXPTL LAB, BRUSSELS, BELGIUM
[2] EUROCETUS, AMSTERDAM, NETHERLANDS
来源：
NOUVELLE REVUE FRANCAISE D HEMATOLOGIE | 1990年 / 32卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：13 / 16
页数：4
相关论文
共 50 条
  • [31] PRODUCTION OF INTERLEUKIN-2 (IL-2) EARLY AFTER BONE-MARROW TRANSPLANTATION (BMT)
    SHERIDAN, JF
    DAVAKIS, LA
    CLOUSE, KA
    TUTSCHKA, PJ
    EXPERIMENTAL HEMATOLOGY, 1985, 13 (05) : 325 - 325
  • [32] AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOLLOWED BY INTERLEUKIN-2 IN CHILDREN WITH ADVANCED LEUKEMIA - A PILOT-STUDY
    MELONI, G
    FOA, R
    TOSTI, S
    VIGNETTI, M
    MANCINI, F
    GUARINI, A
    MARCHIS, D
    GAVOSTO, F
    MANDELLI, F
    LEUKEMIA, 1992, 6 (08) : 780 - 785
  • [33] Oral tuberculosis following autologous bone marrow transplantation for Hodgkin's disease with interleukin-2 and alpha-interferon immunotherapy
    Toren, A
    Ackerstein, A
    Gazit, D
    Or, R
    Raveh, D
    Kupolovicz, U
    Engelhard, D
    Nagler, A
    BONE MARROW TRANSPLANTATION, 1996, 18 (01) : 209 - 210
  • [34] IMMUNOTHERAPY WITH INTERLEUKIN-2 WITH OR WITHOUT LYMPHOKINE-ACTIVATED KILLER-CELLS AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR MALIGNANT-LYMPHOMA - A FEASIBILITY TRIAL
    BENYUNES, MC
    HIGUCHI, C
    YORK, A
    LINDGREN, C
    THOMPSON, JA
    BUCKNER, CD
    FEFER, A
    BONE MARROW TRANSPLANTATION, 1995, 16 (02) : 283 - 288
  • [35] ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR RECURRENCE OF LEUKEMIA AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    SCHWELLA, N
    SCHWERDTFEGER, R
    KONIG, V
    BLASCZYK, R
    SCHMID, H
    SCHMIDTWOLF, I
    HENZE, G
    SIEGERT, W
    TRANSPLANTATION, 1994, 57 (08) : 1263 - 1265
  • [36] Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients
    Messina, C
    Zambello, R
    Rossetti, F
    Gazzola, MV
    Varotto, S
    Destro, R
    Basso, G
    Semenzato, G
    Zanesco, L
    BONE MARROW TRANSPLANTATION, 1996, 17 (05) : 729 - 735
  • [37] IMMUNOTHERAPY OF MINIMAL RESIDUAL DISEASE (MRD) BY ALLOGENEIC PERIPHERAL-BLOOD LYMPHOCYTES FOLLOWING AUTOLOGOUS BONE-MARROW TRANSPLANTATION (ABMT) - IMMUNOLOGICAL EVALUATION
    MORECKI, S
    ACKERSTEIN, A
    NAGLER, A
    PUYESKY, Y
    OR, R
    NAPARSTEK, E
    DRAKOS, P
    KAPELUSHNIK, J
    DELUIKINA, M
    SLAVIN, S
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 134 - 134
  • [38] INTERLEUKIN-2 IMMEDIATELY AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC-LEUKEMIA - A PHASE-I STUDY
    WEISDORF, DJ
    ANDERSON, PM
    BLAZAR, BR
    UCKUN, FM
    KERSEY, JH
    RAMSAY, NKC
    TRANSPLANTATION, 1993, 55 (01) : 61 - 66
  • [39] INFLUENCE OF EXOGENOUS INTERLEUKIN-2 ON THE PROLIFERATION OF LYMPHOCYTES FROM NORMAL DONORS AND FROM PATIENTS AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION
    BORRADORI, L
    HIRT, A
    BAUMGARTNER, C
    MORELL, A
    ACTA HAEMATOLOGICA, 1987, 77 (03) : 129 - 134
  • [40] INTERLEUKIN-2 AND SYNGENEIC BONE-MARROW TRANSPLANTATION IN A MURINE FIBROSARCOMA MODEL
    HO, SP
    STEBLER, B
    ERSHLER, WB
    LYMPHOKINE AND CYTOKINE RESEARCH, 1991, 10 (1-2): : 101 - 104
12345